Publication | Open Access

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

Lymphoid NeoplasiaTransplantationMarrow TransplantationImmunotherapyMedicineStem Cell TransplantationImmunologyHematologyPathologyClassical HodgkinRadiation OncologyOncologyCell TransplantationAutologous Stem-cell TransplantationBrentuximab VedotinHealth Sciences